Clinical Trial MilestonesThe completion of the Phase 2 BMT-801 clinical trial is a significant milestone for Palatin as it focuses on the obesity space, which is seen as a key driver of the company's long-term success.

Market ValuationThe valuation of Palatin's stock appears attractive based on the initial addressable market size, supporting the Buy rating and price target.

Obesity Treatment InitiativesPalatin is developing next-gen selective MC4R agonists for obesity and weight management, with IND-enabling activities set to begin shortly.

Bears Say

Cash PositionThe company ended the quarter with $3.4 million in cash, which does not include a recent equity raise of $4.3 million this month.

Clinical Trial UncertaintyPalatin may need to achieve more than 7-8% weight loss from baseline with a comparable or better safety profile using its combination approach to achieve positive investor sentiment.

Funding ChallengesFactors that could impede reaching the price target include failed or inconclusive clinical trials or the inability to secure adequate funding for drug development.

Options Prices

Currently, No data available

---

Ownership Overview

7.91%

Insiders

1.63%

Mutual Funds

0.09% Other Institutional Investors

90.37% Public Companies and Individual Investors

Detailed Ownership Overview >

PTNT FAQ

What was Palatin Technologies, Inc.’s price range in the past 12 months?

Palatin Technologies, Inc. lowest stock price was $0.04 and its highest was $1.87 in the past 12 months.

What is Palatin Technologies, Inc.’s market cap?

Palatin Technologies, Inc.’s market cap is $6.44M.

When is Palatin Technologies, Inc.’s upcoming earnings report date?

Palatin Technologies, Inc.’s upcoming earnings report date is Oct 07, 2025 which is in 80 days.

How were Palatin Technologies, Inc.’s earnings last quarter?

Palatin Technologies, Inc. released its earnings results on May 14, 2025. The company reported -$0.18 earnings per share for the quarter, missing the consensus estimate of -$0.17 by -$0.01.

Is Palatin Technologies, Inc. overvalued?

According to Wall Street analysts Palatin Technologies, Inc.’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Palatin Technologies, Inc. pay dividends?

Palatin Technologies, Inc. does not currently pay dividends.

What is Palatin Technologies, Inc.’s EPS estimate?

Palatin Technologies, Inc.’s EPS estimate is -0.19.

How many shares outstanding does Palatin Technologies, Inc. have?

Palatin Technologies, Inc. has 46,479,862 shares outstanding.

What happened to Palatin Technologies, Inc.’s price movement after its last earnings report?

Palatin Technologies, Inc. reported an EPS of -$0.18 in its last earnings report, missing expectations of -$0.17. Following the earnings report the stock price went up 11.111%.

Which hedge fund is a major shareholder of Palatin Technologies, Inc.?

Currently, no hedge funds are holding shares in PTNT

Company Description

Palatin Technologies, Inc.

Palatin Technologies, Inc., a biopharmaceutical company, develops targeted receptor-specific therapeutics for the treatment of various diseases in the United States. The company's lead product is Vyleesi, a melanocortin receptor (MCr) agonist for the treatment of premenopausal women with hypoactive sexual desire disorder. It is also developing oral PL8177, a selective MC1r agonist peptide that has completed Phase I clinical trial for the treatment of inflammatory bowel diseases. In addition, the company engages in the development of PL9643, a peptide melanocortin agonist active at multiple MCrs, including MC1r and MC5r for anti-inflammatory ocular indications, such as dry eye disease; and melanocortin peptides for diabetic retinopathy. Further, it is developing PL3994, a natriuretic peptide receptor (NPR)-A agonist and synthetic mimetic of the endogenous neuropeptide hormone atrial natriuretic peptide for cardiovascular indications; and PL5028, an NPR-A and NPR-binder to treat cardiovascular and fibrotic diseases, including reducing cardiac hypertrophy and fibrosis. The company was incorporated in 1986 and is based in Cranbury, New Jersey.

PTNT Earnings Call

Q3 2025

0:00 / 0:00

Earnings Call Sentiment|Neutral

The earnings call presented a mixed view with significant achievements in reducing net loss and promising clinical trial results. However, challenges remain with the absence of product sales and a decrease in cash position. The company is actively pursuing strategic partnerships to enhance its future prospects.Read More>